Predict your next investment

Polyplus-transfection company logo
Corporation
HEALTHCARE | Biotechnology
polyplus-transfection.com

See what CB Insights has to offer

Founded Year

2001

Stage

Acq - Fin - II | Alive

Total Raised

$3.24M

Valuation

$0000 

About Polyplus-transfection

Polyplus-transfection focuses on the development of innovative solutions for the delivery of nucleic acids in research and therapeutics.On February 24th, 2020, Polyplus-transfection was acquired by Warburg Pincus at a valuation of $500M.

Polyplus-transfection Headquarter Location

850 bd Sebastien Brant

Illkirch-Strasbourg, 67400,

France

33 (0)3 90 40 61 80

Latest Polyplus-transfection News

Transfection Reagents & Equipment Competitor Analysis Report - Global Forecast to 2026

Oct 1, 2021

Report - Global Forecast to 2026" - https://www.reportlinker.com/p06148959/?utm_source=GNW 47% to reach USD 3,550.80 Million by 2026. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Transfection Reagents & Equipment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. "Agilent Technologies, Inc. scored highest as a forefront vendor in FPNV Positioning Matrix for Transfection Reagents & Equipment Market" Forefront are rated highly by the users for product satisfaction and have substantially good business strategy scores. F-Forefront include Agilent Technologies, Inc., Bio–Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Cytiva, Lonza Group AG, Qiagen N.V., and Promega Corporation. "BioVision Inc. scored highest as a pathfinder and expected to the upcoming forefront in next couple of years" Pathfinder have significant product satisfaction ratings but somehow lack business strategy as compared to forefronts and vitals. P-Pathfinder include BioVision Inc., Applied Biological Materials, Inc., and Bex Co.,ltd.. "SBS Genetech Co., Ltd. named as an upcoming vendor to watch in Transfection Reagents & Equipment Market" Niche solutions cater to the need of comparatively smaller segment of the overall market. They do not have the business strategy of the Forefront. They may have been rated positively on product satisfaction but have not yet received enough reviews to validate them. N-Niche include SBS Genetech Co., Ltd., Polyplus-Transfection SA, Mirus Bio LLC, and Altogen Biosystems. "Innovative offerings by MaxCyte, Inc. expected to increase its product satisfaction level for Transfection Reagents & Equipment Market in upcoming years" Vital have comparatively good business strategy but have not yet achieved the business strategy of the Forefront. However, they have low product satisfaction ratings. V-Vital include MaxCyte, Inc., PerkinElmer, Inc., GeneCopoeia, Inc., Tecan Trading AG, and Takara Bio Inc.. Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. Competitive Scenario: The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service. Company Usability Profiles: The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Transfection Reagents & Equipment Market, including Agilent Technologies, Inc., Altogen Biosystems, Applied Biological Materials, Inc., Bex Co.,ltd., BioVision Inc., Bio–Rad Laboratories, Inc., Cytiva, GeneCopoeia, Inc., Lonza Group AG, MaxCyte, Inc., Mirus Bio LLC, PerkinElmer, Inc., Polyplus-Transfection SA, Promega Corporation, Qiagen N.V., SBS Genetech Co., Ltd., Takara Bio Inc., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Polyplus-transfection

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Polyplus-transfection is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Polyplus-transfection Patents

Polyplus-transfection has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/22/2015

6/13/2017

Molecular biology, NMDA receptor antagonists, Amino acids, Biotechnology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/22/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/13/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, NMDA receptor antagonists, Amino acids, Biotechnology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Polyplus-transfection Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Polyplus-transfection Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.